Please login to the form below

Not currently logged in
Email:
Password:

kidney cancer

This page shows the latest kidney cancer news and features for those working in and with pharma, biotech and healthcare.

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

The combination of Opdivo and Yervoy lies at the heart of much of Bristol-Myers Squibb’s ambition in immuno-oncology, and an FDA approval for the pairing in kidney cancer ... RCC is the most common type of kidney cancer in adults, accounting for around

Latest news

  • AZ pushes back data read-out from MYSTIC lung cancer trial AZ pushes back data read-out from MYSTIC lung cancer trial

    a high reading indicates more markers on the cancer cell surface that make them vulnerable to this type of therapy. ... Since MYSTIC’s first data read-out BMS has also reported positive overall survival results for Opdivo and Yervoy in kidney cancer -

  • BMS gets OK for monthly Opdivo dosing BMS gets OK for monthly Opdivo dosing

    cancer. It is competing in the marketplace with two other PD-1 inhibitors - Merck &Co/MSD’s Keytruda (pembrolizumab) and Roche’s Tecentriq (atezolizumab) - as well as PD-L1 inhibitors Imfinzi ... The new monthly injection can be used in a range of

  • Pfizer’s leukaemia drug Mylotarg backed for use in EU Pfizer’s leukaemia drug Mylotarg backed for use in EU

    There was worse news for Puma Biotechnology - which has its application to market Nerlyx (neratinib) for breast cancer turned down - and also Pfizer whose application to extend the indications of Sutent ... sunitinib) to include it use to prevent the

  • NICE backs EUSA's RCC treatment Fotivda NICE backs EUSA's RCC treatment Fotivda

    the lives of those patients suffering from cancer.”. ... According to Cancer Research UK, around 12 people in the UK die every day of kidney cancer, with RCC being the most common form of kidney cancer, accounting for 80% of

  • Roche unveils data for Tecentriq/Avastin combo in kidney cancer Roche unveils data for Tecentriq/Avastin combo in kidney cancer

    Roche unveils data for Tecentriq/Avastin combo in kidney cancer. Patients on the combo had a lengthier PFS than those on Pfizer’s Sutent. ... Pairing Roche’s PD-L1 inhibitor Tecentriq with Avastin reduces progression-free survival in patients with

More from news
Approximately 24 fully matching, plus 127 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    Novartis' pipeline includes more than 25 new molecular entities targeting key oncogenic pathways including: Gleevec and its follow-up Tasigna (blood-cancer); Afinitor (kidney cancer and recently approved for breast cancer); ... Additional revenues for

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic ... This protracted process is indicative of the now

  • Pharma investment in Indonesia Pharma investment in Indonesia

    Under this universal scheme, all healthcare services and drugs for major diseases, such as cancer, chronic kidney disease etc.

  • Interview: David Haslam, NICE Interview: David Haslam, NICE

    NHS Diabetes and Kidney Care and the National Cancer Action Team, have been amalgamated into more wide-reaching bodies that are aiming to reshape the healthcare environment in England. ... UK. Referencing the industry's work in HIV and cancer, Prof

  • Country report: The healthcare market in Japan Country report: The healthcare market in Japan

    Colorectal cancer. 7. Liver cancer. 8. Suicide. 9. Kidney disease. 10. ... The largest therapeutic category is Renin-angiotensin system agents (antihypertensive), followed by anti-neoplastics (cancer drugs).

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Mirna hires former Pfizer director as CMO Mirna hires former Pfizer director as CMO

    Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time ... This background will benefit Mirna, which has just

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • A stumble, but not a fall – what’s next for Opdivo?

    and renal cell carcinoma (kidney cancer). ... Rubbing salt into BMS’ s wounds, Merck's  Keytruda snagged a new FDA approval in head-and-neck cancer.

  • Immuno-oncology; bringing patients closer to treatment

    cure; immunotherapies offer positive news for all stakeholders involved in the fight against cancer. ... Immunotherapies can treat head, neck, lung, prostate, renal, multiple myeloma, AML, ALL and kidney cancer.

  • Oncology drugs under AMNOG

    Pfizer’ s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines. ... Consistent with EMA market authorisations for other kidney cancer

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics